Final negotiation |
Master agreement |
34 |
62 |
< 0.0000 |
−33 |
0 |
Previously negotiated terms |
46 |
57 |
0.034 |
−22 |
0.001 |
Multicenter clinical trial |
54 |
58 |
0.271 |
6 |
0.389 |
CRO |
59 |
53 |
0.865 |
6 |
0.255 |
Investigator initiated |
70 |
53 |
0.989 |
15 |
0.088 |
Full execution |
Master agreement |
99 |
104 |
0.23 |
−10 |
0.165 |
Previously negotiated terms |
88 |
106 |
0.009 |
−22 |
0.007 |
Multicenter clinical trial |
103 |
100 |
0.728 |
8 |
0.401 |
CRO |
115 |
99 |
0.992 |
16 |
0.019 |
Investigator initiated |
107 |
103 |
0.682 |
9 |
0.437 |
IRB approval |
Master agreement |
67 |
64 |
0.684 |
2 |
0.764 |
Previously negotiated terms |
61 |
66 |
0.237 |
−5 |
0.474 |
Multicenter clinical trial |
67 |
56 |
0.946 |
11 |
0.154 |
CRO |
N/A |
N/A |
N/A |
11 |
0.057 |
Investigator initiated |
62 |
65 |
0.363 |
6 |
0.514 |
Contract and IRB approval |
Master agreement |
126 |
142 |
< 0.062 |
−16 |
0.139 |
Previously negotiated terms |
128 |
140 |
0.137 |
−16 |
0.182 |
Multicenter clinical trial |
135 |
148 |
0.134 |
0 |
0.995 |
CRO |
154 |
131 |
0.986 |
27 |
0.011 |
Investigator initiated |
169 |
133 |
0.993 |
36 |
0.033 |